A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.

Trial Profile

A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Acronyms TACTI-mel
  • Sponsors Immutep Limited
  • Most Recent Events

    • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
    • 08 Nov 2017 Results from patients in the first two cohorts (n = 12) of this trial presented in a Prima BioMed media release.
    • 08 Nov 2017 According to a Prima BioMed media release, results from patients in the first two cohorts (n = 12) of this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting. The third cohort of patients is being treated with 30 mg doses.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top